Suppr超能文献

胆管癌可起源于小鼠的肝细胞。

Cholangiocarcinomas can originate from hepatocytes in mice.

机构信息

Department of Bioengineering and Therapeutic Sciences, UCSF, San Francisco, CA, USA.

出版信息

J Clin Invest. 2012 Aug;122(8):2911-5. doi: 10.1172/JCI63212. Epub 2012 Jul 17.

Abstract

Intrahepatic cholangiocarcinomas (ICCs) are primary liver tumors with a poor prognosis. The development of effective therapies has been hampered by a limited understanding of the biology of ICCs. Although ICCs exhibit heterogeneity in location, histology, and marker expression, they are currently thought to derive invariably from the cells lining the bile ducts, biliary epithelial cells (BECs), or liver progenitor cells (LPCs). Despite lack of experimental evidence establishing BECs or LPCs as the origin of ICCs, other liver cell types have not been considered. Here we show that ICCs can originate from fully differentiated hepatocytes. Using a mouse model of hepatocyte fate tracing, we found that activated NOTCH and AKT signaling cooperate to convert normal hepatocytes into biliary cells that act as precursors of rapidly progressing, lethal ICCs. Our findings suggest a previously overlooked mechanism of human ICC formation that may be targetable for anti-ICC therapy.

摘要

肝内胆管癌(ICC)是一种预后不良的原发性肝癌。由于对 ICC 生物学的了解有限,有效的治疗方法的发展一直受到阻碍。尽管 ICC 在位置、组织学和标志物表达上存在异质性,但目前认为它们总是来源于胆管、胆管上皮细胞(BEC)或肝祖细胞(LPC)的细胞。尽管缺乏实验证据表明 BEC 或 LPC 是 ICC 的起源,但其他肝细胞类型尚未被考虑。在这里,我们表明 ICC 可以起源于完全分化的肝细胞。使用肝细胞命运追踪的小鼠模型,我们发现激活的 NOTCH 和 AKT 信号协同作用将正常肝细胞转化为胆管细胞,这些胆管细胞作为快速进展、致命的 ICC 的前体细胞。我们的研究结果表明,人类 ICC 形成的一种以前被忽视的机制,可能成为抗 ICC 治疗的靶点。

相似文献

1
Cholangiocarcinomas can originate from hepatocytes in mice.胆管癌可起源于小鼠的肝细胞。
J Clin Invest. 2012 Aug;122(8):2911-5. doi: 10.1172/JCI63212. Epub 2012 Jul 17.
2
Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice.Notch2 控制小鼠肝细胞源性胆管癌的形成。
Oncogene. 2018 Jun;37(24):3229-3242. doi: 10.1038/s41388-018-0188-1. Epub 2018 Mar 16.

引用本文的文献

4
[Pathology of liver tumours in animal models].[动物模型中肝脏肿瘤的病理学]
Pathologie (Heidelb). 2025 Jul 14. doi: 10.1007/s00292-025-01452-8.
8
CLDN18.2: a potential nanotherapeutic target for cholangiocarcinoma.紧密连接蛋白18.2:胆管癌潜在的纳米治疗靶点
Front Pharmacol. 2025 Mar 26;16:1559558. doi: 10.3389/fphar.2025.1559558. eCollection 2025.

本文引用的文献

5
Clinical diagnosis and staging of cholangiocarcinoma.胆管癌的临床诊断和分期。
Nat Rev Gastroenterol Hepatol. 2011 Aug 2;8(9):512-22. doi: 10.1038/nrgastro.2011.131.
7
Risk factors for cholangiocarcinoma.胆管癌的危险因素。
Hepatology. 2011 Jul;54(1):173-84. doi: 10.1002/hep.24351.
9
Intrahepatic cholangiocarcinoma: new insights in pathology.肝内胆管细胞癌:病理学新见解。
Semin Liver Dis. 2011 Feb;31(1):49-60. doi: 10.1055/s-0031-1272839. Epub 2011 Feb 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验